

# CITATION REPORT

List of articles citing

**Docosahexaenoic acid for the treatment of fatty liver:  
randomised controlled trial in children**

**DOI: 10.1016/j.numecd.2012.10.010**

**Nutrition, Metabolism and Cardiovascular Diseases,  
2013, 23, 1066-70.**

**Source:** <https://exaly.com/paper-pdf/55584677/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
105	The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. <b>2013</b> , 16, 957-60		49
104	Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. <b>2014</b> , 9, e88005		94
103	Non-alcoholic fatty liver disease in children: focus on nutritional interventions. <b>2014</b> , 6, 4691-705		24
102	Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. <b>2014</b> , 15, 2501-11		6
101	Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. <b>2014</b> , 39, 1276-85		269
100	Pediatric non-alcoholic fatty liver disease: an increasing public health issue. <b>2014</b> , 173, 131-9		84
99	Pediatric non-alcoholic fatty liver disease: recent advances. <b>2014</b> , 38, 419-22		14
98	Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. <b>2014</b> , 37, 739-744		10
97	Review article: the management of paediatric nonalcoholic fatty liver disease. <b>2014</b> , 40, 1155-70		33
96	Yield of diagnostic tests in obese children with an elevated alanine aminotransferase. <b>2015</b> , 104, e557-63		4
95	Paediatric non-alcoholic fatty liver disease: an overview. <b>2015</b> , 16, 393-405		38
94	Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. <b>2015</b> , 7, 2597-602		38
93	Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease. <b>2015</b> , 16, 25168-98		76
92	Docosahexaenoic Acid Levels in Blood and Metabolic Syndrome in Obese Children: Is There a Link?. <b>2015</b> , 16, 19989-20000		6
91	Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease. <b>2015</b> , 21, 10621-35		30
90	A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2015</b> , 25, 734-41	4.5	60
89	Docosahexaenoic acid and non-alcoholic fatty liver disease in obese children: a novel approach?. <b>2015</b> , 13, 109		3

88	The use of omega-3 Fatty acids in nonalcoholic Fatty liver disease: the end of the road or a new beginning?. <b>2015</b> , 166, 1335-7	4
87	Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation. <b>2015</b> , 99, 25-34	24
86	Beneficial effects of E3 PUFA in children on cardiovascular risk factors during childhood and adolescence. <b>2015</b> , 120, 72-9	27
85	Pharmacotherapy for Nonalcoholic Fatty Liver Disease. <b>2015</b> , 35, 338-48	21
84	Alcoholic Liver Disease: Update on the Role of Dietary Fat. <b>2016</b> , 6, 1	74
83	Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. <b>2016</b> , 11, e0157246	41
82	Upregulation of rat liver PPAR $\gamma$ /GF21 signaling by a docosahexaenoic acid and thyroid hormone combined protocol. <b>2016</b> , 42, 638-646	14
81	Pediatric Non-alcoholic Fatty Liver Disease. <b>2016</b> , 18, 24	26
80	Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans. <b>2016</b> , 14, 417-430	18
79	Dried blood spot omega-3 and omega-6 long chain polyunsaturated fatty acid levels in 7-9 year old Zimbabwean children: a cross sectional study. <b>2016</b> , 16, 14	8
78	Analysis of breast milk fatty acid composition using dried milk samples. <b>2016</b> , 11, 1	26
77	Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial. <b>2016</b> , 35, 578-86	65
76	Role of Lipogenesis and Lipid Desaturases in Non-alcoholic Fatty Liver Disease. <b>2016</b> , 143-164	
75	Pediatric liver diseases: current challenges and future perspectives. <b>2016</b> , 10, 255-65	13
74	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. <b>2016</b> , 150, 1798-810	84
73	Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. <b>2016</b> , 65, 1161-71	43
72	Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease. <b>2016</b> , 313-337	
71	Dietary docosahexaenoic acid reverses nonalcoholic steatohepatitis and fibrosis caused by conjugated linoleic acid supplementation in mice. <b>2016</b> , 20, 443-452	2

70	Nutritional therapy for nonalcoholic fatty liver disease. <b>2016</b> , 29, 1-11	72
69	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. <b>2016</b> , 53, 106-20	28
68	Non-Alcoholic Steatohepatitis in Childhood. <b>2017</b> , 227-240	1
67	A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice. <b>2017</b> , 42, 149-159	4
66	Systematic Review: Nutrition and Physical Activity in the Management of Paediatric Nonalcoholic Fatty Liver Disease. <b>2017</b> , 65, 141-149	29
65	Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. <b>2017</b> , 42, 948-954	33
64	Current Concepts in Pediatric Nonalcoholic Fatty Liver Disease. <b>2017</b> , 46, 217-231	14
63	NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). <b>2017</b> , 64, 313-334	382
62	Monitoring the efficacy of omega-3 supplementation on liver steatosis and carotid intima-media thickness: a pilot study. <b>2017</b> , 3, 201-211	3
61	Long-term challenges and perspectives of pre-adolescent liver disease. <b>2017</b> , 2, 435-445	10
60	The pharmacological management of NAFLD in children and adolescents. <b>2017</b> , 10, 1225-1237	9
59	Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. <b>2017</b> , 26, 519-541	213
58	A Review of Recruitment, Adherence and Drop-Out Rates in Omega-3 Polyunsaturated Fatty Acid Supplementation Trials in Children and Adolescents. <b>2017</b> , 9,	18
57	The effect of omega-3 unsaturated fatty acids on non-alcoholic fatty liver disease: A systematic review and meta-analysis of RCTs. <b>2017</b> , 33, 1022-1028	17
56	The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. <b>2017</b> , 4,	49
55	The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. <b>2017</b> , 2017, 8162421	85
54	Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. <b>2018</b> , 58, 28-36	21
53	The potential role of statins in treating liver disease. <b>2018</b> , 12, 331-339	10

52	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. <b>2018</b> , 64, 135-146	61
51	Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: A systematic review and meta-analysis of randomized controlled trials. <b>2018</b> , 37, 516-521	38
50	Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. <b>2018</b> , 37, 37-55	66
49	Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease. <b>2018</b> , 181, 108-125	64
48	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. <b>2018</b> , 33, 86-98	71
47	Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <b>2018</b> , 22, 189-199	19
46	Omega-3 polyunsaturated fatty acids protect human hepatoma cells from developing steatosis through FFA4 (GPR120). <b>2018</b> , 1863, 105-116	27
45	Effective Food Ingredients for Fatty Liver: Soy Protein E Conglycinin and Fish Oil. <b>2018</b> , 19,	8
44	A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. <b>2018</b> , 58, 1-16	21
43	Omega-3 Fatty Acids and Fatty Liver Disease in Children. <b>2018</b> , 85, 59-77	3
42	Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. <b>2018</b> , 20, 315-329	16
41	Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease. <b>2018</b> , 76, 581-602	49
40	Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. <b>2019</b> , 17, 1457-1476.e7	23
39	NAFLD in children: new genes, new diagnostic modalities and new drugs. <b>2019</b> , 16, 517-530	105
38	Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management. <b>2019</b> , 10, 89-97	15
37	Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. <b>2019</b> , 9, 12848	19
36	Effects of abomasal infusions of fatty acids and one-carbon donors on hepatic ceramide and phosphatidylcholine in lactating Holstein dairy cows. <b>2019</b> , 102, 7087-7101	7
35	Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. <b>2019</b> , 5, 11-21	19

34	Clinical application of the dried milk spot method for measuring tocilizumab concentrations in the breast milk of patients with rheumatoid arthritis. <b>2019</b> , 22, 1130-1137	6
33	Dietary Management of Nonalcoholic Fatty Liver Disease (NAFLD) by n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation. <b>2019</b> , 373-389	2
32	Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH. <b>2019</b> , 9, 2045	27
31	Wnt- $\beta$ -catenin signalling in liver development, health and disease. <b>2019</b> , 16, 121-136	156
30	The influence of dietary fatty acids on liver fat content and metabolism. <b>2020</b> , 79, 30-41	22
29	The pharmacological treatment of nonalcoholic fatty liver disease in children. <b>2020</b> , 13, 1219-1227	2
28	High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. <b>2020</b> , 330, 109199	25
27	Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. <b>2020</b> , 12,	4
26	Effect of Fish Oil on Insulin Sensitivity in Children: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. <b>2021</b> , 45, 531-538.e1	1
25	Supplementation with Docosahexaenoic Acid and Vitamin E Improves Hepatic Triglyceride Accumulation Induced by High-Fat Diet in Mice. <b>2021</b> , 123, 2000224	1
24	Composition of Dietary Fatty Acids and Health Risks in Japanese Youths. <b>2021</b> , 13,	0
23	Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease. <b>2021</b> , 12, 656441	5
22	Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes. <b>2021</b> , 12, 639548	11
21	Polycystic Ovary Syndrome in Insulin-Resistant Adolescents with Obesity: The Role of Nutrition Therapy and Food Supplements as a Strategy to Protect Fertility. <b>2021</b> , 13,	8
20	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. <b>2021</b> , 7, CD013157	2
19	Effect of omega-3 supplementation on fatty liver and visceral adiposity indices in diabetic patients with non-alcoholic fatty liver disease: A randomized controlled trial. <b>2021</b> , 44, 130-135	6
18	Nonalcoholic Fatty Liver Disease in Children: Spectrum and Consequences. <b>2021</b> , 55, 39-52	
17	Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. <b>2015</b> , 10, e0133496	58

16	Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. <b>2016</b> , 11, e0162368	57
15	The Impact of Nutrition on the Autonomic Nervous System. <b>2016</b> , 3, 1-16	7
14	Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease. <b>2020</b> , 27, 5250-5272	26
13	Pediatric Nonalcoholic Fatty Liver Disease. <b>2016</b> , 293-307	
12	Treatment of Nonalcoholic Fatty Liver Disease in Children: A Systematic Review. <b>2017</b> , 6,	
11	Omega-3 for nonalcoholic fatty liver disease in children. <b>2019</b> , 65, 34-38	1
10	Effect of Vitamin D and Docosahexaenoic Acid Co-Supplementation on Vitamin D Status, Body Composition, and Metabolic Markers in Obese Children: A Randomized, Double Blind, Controlled Study.. <b>2022</b> , 14,	1
9	Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.. <b>2021</b> , 9,	1
8	Can omega-3 fatty acids be beneficial in pediatric NAFLD? A systematic review and meta-analysis.. <b>2022</b> , 1-9	1
7	Docosahexaenoic Acid as the Bidirectional Biomarker of Dietary and Metabolic Risk Patterns in Chinese Children: A Comparison with Plasma and Erythrocyte. <b>2022</b> , 14, 3095	
6	Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) [April 2022] AWMF Registration No.: 021025. <b>2022</b> , 60, e733-e801	o
5	Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [April 2022] AWMF-Registernummer: 021025. <b>2022</b> , 60, 1346-1421	o
4	Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: A systematic review and network meta-analysis. <b>2022</b> , 108294	o
3	PNPLA3 I148M and response to treatment for hepatic steatosis. A systematic review..	o
2	Special Population. <b>2023</b> , 27, 471-482	o
1	Adipose-targeted SWELL1 deletion exacerbates obesity- and age-related nonalcoholic fatty liver disease. <b>2023</b> , 8,	o